Opyl Limited announced the signing of two important partnerships with patient advocacy organizations -NeuroEndocrine Cancer Australia and Pancare Foundation. Relationships with patient advocates support the expansion and success of Opin, Opyl's rapidly growing global clinical trial recruitment platform. Relationships with patient advocates are important in being able to swiftly access patient communities online respectfully, ethically, and appropriately and thus accelerate recruitment to trials via Opin -- particularly with rare and aggressive cancers where trials may provide a very significant treatment benefit and in situations where a patient may have a life limiting condition.

A relationship with Opin, ensures that Neuroendocrine Cancer Australia and Pancare Foundation's patient communities are aware of every active, relevant clinical trial and are given every opportunity to participate in those trials. It also ensures that patients can access the newest medicines and diagnostics in development. Under the agreements, the Opin team will advocate, alongside patient communities, to attract more cancer trials and research investment to Australia, particularly trials for therapies and diagnostics addressing rare and aggressive cancers, as well as apply for joint grants, publish papers, and develop patient co-design opportunities to improve clinical trial design and recruitment service delivery.